Teva Statement on European Commission Decision; Company to Appeal
Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, […]
TSX News -
Bombardier Defense Proudly Delivers Eighth Global Aircraft to the U.S. Air Force Battlefield Airborne Communications Node Program
Rendering of the BACN 8 aircraft Bombardier Defense delivered the eighth Bombardier Global aircraft to the United States Air Force […]
TSX News -
Notice of Knight Therapeutics’ Third Quarter 2024 Results Conference Call
MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, […]
500 Cycles Major Milestone: Novacium’s Silicon-Based Anode Batteries Demonstrate High Capacity and High Durability
18650 batteries with GEN3 silicon-based materials deliver unmatched capacity and durability [1], providing 3,301 milliampere-hours (mAh) of capacity with 85% […]
Red Pine Discovers Significant Gold Mineralization in Faulted Extension of the Jubilee Shear on the Wawa Gold Project
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) (“Red Pine” or the “Company”) […]
Angus Gold Commences Fall Drilling Program on Dorset Gold Zone, Golden Sky Project, Wawa
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Angus Gold Inc. (TSX-V: GUS | OTC: ANGVF) (“Angus” or the “Company”) is […]
Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually
DURHAM, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated […]
InHouse by MariMed Launches Help on the Homefront, to Support Veterans Facing Housing Challenges
NORWOOD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — InHouse™, MariMed’s (“MariMed”) (CSE: MRMD) (OTCQX: MRMD) high quality, value-priced line of […]
TSX News -
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages […]
HII Reports Third Quarter 2024 Results and Provides Updated Outlook
NEWPORT NEWS, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) today reported results for the third quarter of […]
